TB500 10mg vial

                                           NOT FOR HUMAN CONSUMPTION

TB-500, also known as Thymosin Beta-4 (Tβ4), is a synthetic peptide derived from a naturally occurring protein found in virtually all human and animal cells. It plays a critical role in cell migration, wound healing, tissue regeneration, and reducing inflammation. Initially discovered in the thymus gland, Thymosin Beta-4 has garnered significant attention in clinical and sports research due to its regenerative and anti-inflammatory properties.

Biological and Chemical Properties

• Name: Thymosin Beta-4 (Tβ4), commonly referred to as TB-500 (synthetic form)

• Structure: 43-amino-acid peptide

• Natural Source: Ubiquitously expressed in various tissues; particularly abundant in wound fluids and platelets

• Administration Route: Subcutaneous or intramuscular injection for experimental purposes

• Half-life: Approximately 24–48 hours (rapid tissue distribution with prolonged regenerative effects)

Mechanism of Action

TB-500 exerts its effects primarily through:

1. Enhanced Cell Migration and Healing

• Promotes cell migration and adhesion, accelerating wound closure and tissue regeneration.

• Influences actin polymerization, essential for cell motility and tissue repair.

2. Angiogenesis (Blood Vessel Formation)

• Stimulates the growth of new blood vessels, improving blood flow, oxygenation, and nutrient delivery to injured tissues.

3. Anti-inflammatory Effects

• Reduces inflammatory cytokines and modulates immune responses, facilitating a faster healing process and reduced scar tissue formation.

4. Tissue Protection and Regeneration

• Exhibits protective effects on cardiac, neural, and muscular tissues, potentially mitigating injury-related damage.

Therapeutic and Experimental Applications

TB-500 demonstrates substantial therapeutic potential across multiple conditions:

1. Musculoskeletal Injuries and Recovery

• Accelerates healing in muscle, tendon, ligament, and joint injuries.

• Popular among athletes and bodybuilders experimentally to speed recovery from soft tissue injuries.

2. Cardiovascular Disease

• Cardioprotective properties following myocardial infarction (heart attack), reducing damage and aiding cardiac repair (animal and preliminary human studies).

3. Wound Healing and Skin Repair

• Significant improvement in wound closure rates, reduced scar formation, and enhanced skin healing in preclinical models.

4. Neuroprotection and Nervous System Regeneration

• Preclinical evidence of neuroprotective benefits in traumatic brain injury (TBI), stroke, and peripheral nerve regeneration.

5. Inflammatory and Autoimmune Conditions

• Experimental potential in treating inflammatory disorders, reducing symptoms, and improving recovery rates.

Dosage and Administration (Experimental Context)

No standardized clinical guidelines exist, as TB-500 remains experimental. Common dosing strategies used in experimental and anecdotal contexts include:

Administration: Usually subcutaneous injection near injury site or general subcutaneous injection.

Safety Profile and Side Effects

TB-500 is generally reported as well-tolerated in limited experimental use. However, due to limited clinical studies, complete safety profiles are unknown.

Commonly Reported (Rare and Mild):

• Mild transient irritation or redness at injection sites.

• Temporary fatigue or headache (rarely reported).

Potential Long-term Risks:

• Limited data on long-term safety in humans.

• Theoretical concerns of promoting uncontrolled angiogenesis or tumor growth, though not confirmed in clinical studies.

Contraindications and Precautions

• Contraindications:

  • Pregnancy and breastfeeding (unknown safety).

  • Known hypersensitivity or allergic reaction to peptides.

• Precautions:

  • Individuals with active or prior malignancies (theoretical risk of angiogenesis).

  • Caution in individuals prone to autoimmune conditions or hyperactive immune responses.

Legal and Regulatory Status

• Approval Status:

  • Not approved by FDA or other regulatory agencies for clinical therapeutic use in humans.

• Availability:

  • Typically marketed as a research peptide "not for human consumption."

• Sports and Doping:

  • Explicitly prohibited by World Anti-Doping Agency (WADA) due to regenerative and performance-enhancing potential.

Current Research Status and Evidence

• Extensive preclinical (animal) studies confirming regenerative potential for muscle, tendon, ligament injuries, cardiovascular damage, and wound healing.

• Limited human clinical studies have been conducted; early trials demonstrate safety and promising efficacy but require further investigation.

• Most current human use remains experimental, anecdotal, or investigational, with ongoing research required for robust validation.

Summary of Potential Benefits and Risks

Future Directions and Research Needs

• Conduct large-scale, randomized, controlled human clinical trials to confirm efficacy, dosage optimization, and safety.

• Long-term studies assessing safety, potential cancer risk, and impacts on immune function.

• Expansion of therapeutic potential investigations into chronic inflammatory, cardiovascular, neurodegenerative, and musculoskeletal conditions.

References 

• Sosne, G., & Kleinman, H. K. (2015). "Thymosin Beta 4 promotes dermal healing." Expert Opinion on Biological Therapy, 15(Suppl 1), S47–S53.

• Goldstein, A. L., & Hannappel, E. (2005). "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 11(9), 421–429.

• Smart, N., Risebro, C. A., & Riley, P. R. (2007). "Thymosin β4 and cardiac repair." Annals of the New York Academy of Sciences, 1112, 82–91.